Zoryl-M4 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 4 mg and Metformin 500 mg, formulated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving peripheral insulin sensitivity, and enhancing glucose uptake in muscle tissues. The extended-release formulation of Zoryl-M4 ensures gradual drug release, promoting sustained plasma concentrations and improved patient compliance. This combination is indicated for patients inadequately controlled on diet and exercise alone or on monotherapy with either agent. Zoryl-M4 aids in reducing fasting and postprandial blood glucose levels, contributing to overall glycemic management and lowering the risk of diabetes-related complications. It is essential to use this medication under medical supervision, considering contraindications such as renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. Regular monitoring of blood glucose, renal function, and potential adverse effects like hypoglycemia or gastrointestinal disturbances is recommended. Zoryl-M4 Tablet PR offers an effective therapeutic option for optimizing glycemic control in type 2 diabetes when lifestyle modifications are insufficient.